Poster Session 2 – Thursday, December 6 7:00 am – 9:00 am
   
  Tumor Cell and Molecular Biology: Tumor Progression, Invasion, and Metastasis
P2-01-01 Early relapses in breast cancer can be prevented by a perioperative NSAID, which would be a solution to a 2000 year old problem
Retsky MW, Baum M, Vaidya JS, Rogers RA, Hrushesky WJ, Demicheli R, Forget P. Harvard TH Chan School of Public Health, Boston, MA; University College London (Emeritus), London, United Kingdom; University College London, London, United Kingdom; University of Southern Carolina (Retired), Columbia, SC; University of Milan, Milan, Italy; University Hospital Brussels, Brussels, Belgium.
P2-01-02 Whole exome sequencing analysis of the progression from ductal carcinoma in situ to invasive ductal carcinoma
Lee JY, Bi R, Pareja F, Geyer FC, Brown D, Wen HY, Norton L, Hicks J, Weigelt B, Reis-Filho JS. Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA.
P2-01-03 Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion
Villodre ES, Larson R, Hu X, Stecklein SR, Gomez K, Finetti P, Krishnamurthy S, Ivan C, Su X, Ueno NT, Van Laere S, Bertucci F, Tripathy D, Vivas-Mejía P, A Woodward W, Debeb BG. University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas at Brownsville, Brownsville, TX; The University of Antwerp, Antwerpen, Belgium; Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France; University of Puerto Rico (UPR) Medical Science Campus and UPR Comprehensive Cancer Center, San Juan, Puerto Rico; MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX.
P2-01-04 Epithelial-mesenchymal transition promotes triple negative breast cancer immune suppression
Williams MM, Christenson JL, O'Neill K, Rogers TJ, Greene LI, Slansky J, Richer JK. University of Colorado Anschutz Medical Campus, Aurora, CO.
P2-01-05 Targeting of casein kinase 1δ inhibits triple negative breast cancer metastasis
Bayle S, Lafitte M, Quereda V, Roush WR, Duckett DR. The Scripps Research Institute, Jupiter, FL; CRBM University Montpellier CNRS, Montpellier, France.
P2-01-06 Intravital imaging of the lung reveals the efficiency of the metastatic cascade
Coste AH, Boriello L, Wang Y, Oktay M, Condeelis JS, Entenberg D. Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY; Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY; Integrated Imaging Program, Albert Einstein College of Medicine, Bronx, NY.
P2-01-07 M2-like tumor-associated macrophages require Tartrate-resistant acid phosphatase as overall function to promote breast cancer metastasis
Dai M-S, Lo H-C, Chen L-C, Janckilla A, Tseng S-F. Hematology/Oncology, Tri-Service General Hospital, Taipei, Taiwan.
P2-01-08 The potential role of CTNND1 (catenin (cadherin-associated protein), Delta 1) in breast cancer bone metastasis
Gong C, Andrew A, Feng Y, Owen S, Liang G, Davies E, Song E, Jiang W. Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Cardiff, United Kingdom; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou City, China; Cardiff Breast Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, United Kingdom.
P2-01-09 ESR1 mutations drive breast cancer metastasis by context-dependent alterations in adhesive and migratory properties
Li Z, Bahreini A, Levine KM, Wang P, Tasdemir N, Montanez MA, Sundd P, Wallace CT, Watkins SC, Chu D, Park BH, Hou W, Mooring MS, Zhu L, Tseng GC, Carroll JS, Atkinson JM, Lee AV, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom.
P2-01-10 Withdrawn
P2-01-11 A peptide with the conserved amino acid residue of integrin α6 inhibits metastasis through disruption of complex formation in breast cancer cells
Itou J, Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Sato F, Toi M. Kyoto University, Kyoto, Japan.
P2-01-12 Detection of circulating cancer stem cells: A novel approach as a predictive marker for breast cancer metastases. This may be especially useful in patients with undetectable circulating epithelial tumor cells
Pizon M, Schott D, Pachmann U, Pachmann K. Transfusion Center Bayreuth, Bayreuth, Germany.
P2-01-13 The splicing factor PHD finger protein 5A inhibits apoptosis to promote breast cancer progression
Zheng Y-Z, Xue M-Z, Shen H-J, Li X-G, Ma D, Gong Y, Hu X, Shao Z-M. Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China; Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; Epigenetics Laboratory, Institutes of Biomedical Sciences and School of Basic Medicine, Shanghai Medical College of Fudan University, Shanghai, China.
P2-01-14 Adipocytes and cancer cell interactions promote leptin receptor expression and drive β-catenin-mediated progression in triple negative breast cancer
Feng Z, Tao Z, Hu X. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-01-15 Inflammatory breast cancer cells are characterized by attenuated SMAD dependent TGFβ signaling leading to impaired cell motility responses
Rypens C, Van Berckelaer C, Billet C, Hauspy J, Bertucci F, Peter V, Dirix L, Van Laere S. University of Antwerp, Wilrijk, Belgium; GZA Hospitals Sint-Augustinus, Wilrijk, Belgium; Institut Paoli-Calmettes, Marseille, France.
P2-01-16 CRISPR-Cas9 screen identifies TMEM106A as a suppressor of breast cancer metastasis
Yang L, Yu S-J, Shao Z-M. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-01-17 Epigenetic and transcriptomic profiling of mammary gland development and tumor models disclose regulators of cell state plasticity
Dravis CP, Chung C-Y, Wahl GM. Salk Institute for Biological Studies, La Jolla, CA.
P2-01-18 Neuropilin 1 is required for fibroblast growth factor receptor-mediated tumor progression
Abdullah A, Tao A, Wendt MK. Purdue University, West Lafayette, IN.
P2-01-19 Sphingosine-1-phosphate affects tumor-associated macrophages in breast cancer patients
Tsuchida J, Nagahashi M, Moro K, Ikarashi M, Koyama Y, Sakata J, Kobayashi T, Kameyama H, Qi Q, Yan L, Takabe K, Wakai T. Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; Breast Surgery, Roswell Park Cancer Institute, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York, Buffalo, NY.
P2-01-20 LAP2alpha, a novel tumor marker candidate is related to metastasis of breast cancer
Hu Y, Qiu J, Zhou M, Li X, Huang Y. The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China; Cancer Institute, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
P2-01-21 Re-activation of mutant p53 with APR-246 suppresses stem-cell like properties and lung metastasis of triple-negative breast cancer cells
Hyder SM, Cook MT, Liang Y. University of Missouri, Columbia, MO; Washburn University, Topeka, KS.
P2-01-22 KLF4 improve prognosis of triple negative breast cancer by suppression of epitherial mesenchymal transition
Nagata T, Sekine S, Arai M, Fujii T. University of Toyama, Toyama, Japan.
P2-01-23 The role of DCC in inhibiting tumor progression in breast cancer
Xing W, Li Q, Cao R, Sun G, Jiang C. China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
P2-01-24 Sulindac and triple negative breast cancer progression
Xi Y, Yi B, Riker A. LSU Health Sciences Center, New Orleans, LA.
P2-01-25 The role of neogenin in inhibiting migration, invasion and metastasis of breast cancer
Xing W, Li Q, Cao R, Sun G, Jiang C. China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
   
  Tumor Cell and Molecular Biology: Metabolism and Breast Cancer
P2-02-01 Inhibition of creatine kinase metabolism represses invasion and sensitizes estrogen-receptor negative breast cancer cells to standard chemotherapies
Barch HP, Krutilina R, Brooks DL, Parke D, Seagroves TN. The University of Tennessee Health Science Center, Memphis, TN.
P2-02-02 The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J. Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN.
P2-02-03 FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
Gruslova A, Sareddy GR, Vadlamudi RK, Viswanadhapalli S, Brenner A. Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX; University of Texas Health at San Antonio, San Antonio, TX.
P2-02-04 CD73 expression regulated by estrogen signaling associates with poor prognosis in estrogen receptor (ER)-positive breast cancer
Katsuta E, Anand V, Yan L, Dasgupta S, Takabe K. Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P2-02-05 Targeting PFKFB3 enzyme induces cell death via reactive oxygen species-mediated toxicity in endocrine therapy-resistant breast cancers
Sengupta S, Sevigny CM, Jones BC, Jin L, Pohlmann PR, Calrke R. Georgetown University, Washington, DC.
P2-02-06 Deregulated lipid metabolism fuels the genesis of estrogen receptor negative breast cancer
Yadav S, Choi M, VanDerway D, Bauer G, Backman V, Khan SA, Clare SE. Northwestern University, Chicago, IL; Northwestern University, Evanston, IL.
P2-02-07 Targeting iron metabolism in breast cancer: Ferroptosis and genome stability
Possemato RL, Sviderskiy VO, Alvarez SW, Terzi EM. New York University School of Medicine, New York.
P2-02-08 Slit2 induced anti-tumor activity may be mediated through metabolism driven immunomodulation
Kaul K, Ahirwar DK, Benej M, Denko N, Ganju R. Comprehensive Cancer Center, The Ohio State University, Columbus; The Ohio State University, Columbus.
P2-02-09 Association between obesity and firmicutes/bacteroidetes ratio in breast cancer patients
An J, Yang J, Lee W-H, Kim JB, Kim J-k, Kim H, Paek SH, Lee JW, Woo J, Kwon H, Lim W, Paik NS, Kim Y-K, Moon B-I. Ewha Womans University School of Medicine, Seoul, Republic of Korea; MD Healthcare Company, Seoul, Republic of Korea.
P2-02-10 Progesterone receptor membrane component-1 interacts with proteins of the cholesterol synthesis pathway resulting in altered cholesterol metabolism in breast cancer cells: Potential mechanism contributing to breast cancer progression
Ludescher M, Stamm N, Niederacher D, Ruckhäberle E, Fehm T, Neubauer H. University Hospital and Medical Faculty of the Heinrich-Heine University, Duesseldorf, Germany.
P2-02-11 Combinational treatment of biguanides and fatty acid β-oxidation inhibitor in triple-negative breast cancers
Park JH, Jung KH, Vithayathil S, Jia D, Kaipparettu BA. Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
P2-02-12 Gain-of-function of mutant P53 elevates glucose uptake via membrane translocation of GLUT1 in breast cancer
Ahn SG, Bae SJ, Yoon CI, Cha C, Park SE, Jeong J. Gangnam Severance Hospital, Seoul, Korea.
P2-02-13 Computational metabolism modeling predicts risk of relapse in breast cancer patients
Zamora P, Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Ferrer-Gómez M, Díaz- Almirón M, López Vacas R, Espinosa E, Fresno Vara JA. Servicio de Oncologia Médica. Hospital Universitario La Paz, Madrid, Spain; Biomedica Molecular Medicine SL, Madrid, Spain; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain; La Paz University Hospital-IdiPAZ, MADRID, Spain.
P2-02-14 Metabolic regulation and drug resistance in c-Src activated triple negative breast cancer
Jung KH, Park JH, Sirupangi T, Jia D, Gandhi N, Pudakalakatti S, Elswood J, Porter W, Putluri N, Zhang XH-F, Chen X, Bhattacharya PK, Creighton CJ, Lewis MT, Rosen JM, Wong L-JC, Das GM, Osborne CK, Rimawi MF, Kaipparettu BA. Baylor College of Medicine, Houston; Center for Theoretical Biological Physics, Rice University, Houston; Roswell Park Cancer Institute, Buffalo; MD Anderson Cancer Center, The University of Texas, Houston; Veterinary Integrative Biosciences, Texas A&M University, College Station; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston.
P2-02-15 All-trans retinoic acid perturbs the lipidomic profiles of luminal breast cancer cells characterized by sensitivity to the anti-proliferative activity of the retinoid
Terao M, Celestini V, Kurosaki M, Vallerga A, Bolis M, Fratelli M, Paroni G, Di Veroli A, Cruciani G, Goracci L, Garattini E. Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; University of Perugia, Perugia, Italy.
P2-02-16 Cancer/testis antigen-Plac1 promotes invasion and metastasis of breast cancer through Furin/NICD/PTEN signaling pathway
Li Y, Chu J, Li J, Tang J, Yin Y. The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
P2-02-17 Metabolism-driven cancer identification with GLUT5-specific molecular probes
Ghosh A, Kannan S, Begoyan VV, Weselinski LJ, Rao S, Tanasova M. Michigan Technological University, Houghton, MI.
   
  Tumor Cell and Molecular Biology: Signaling Pathways
P2-03-01 Akt inhibition associated with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC)
Marks DK, Gartrell RD, Pan Q, El Asmar M, Hart TD, Esancy CL, Lu Y, Yu J, Hibshoosh H, Connolly E, Kalinsky K, Saenger YM. Columbia University Irving Medical Center, New York, NY; Columbia University, New York, NY; St. Jude Children's Research Hospital, Memphis, TN.
P2-03-02 Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER+ breast cancer
Campbell C, Mathew J, Ellis I, Finlay P, Green A, Bradbury I, Borgquist S, Elebro K, Politz O, Haegebarth A, Gee JMW, Robertson JF. Frontier Science Scotland, Inverness-SHIRE, United Kingdom; Peterborough City Hospital, Peterborough, United Kingdom; Nottingham University Hospital, Nottingham, United Kingdom; Cardiff University, Cardiff, United Kingdom; Aarhus University, Aarhus, Denmark; Skåne University Hospital, Malmö, Sweden; Bayer, Berlin, Germany.
P2-03-03  BRG1-SOX4 mediates a novel and essential signaling network that activates PI3K/Akt signaling in TNBC
Gatza ML, Angus SP, Khella CA, Tong K, Verzi M, Mehta GA. Rutgers Cancer Institute, New Brunswick, NJ; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
P2-03-04 A novel druggable target upstream of Notch: MEK5/ERK5 signaling regulates Jagged-1 and Notch1 expression in triple negative breast cancer stem cells
Ucar DA, Matossian MD, Hoang-Barnes VT, Hossain FM, Gupta M, Burks HE, Wright TD, Cavanaugh J, Flaherty P, Burow ME, Miele L. LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD.
P2-03-05 S100A7 enhances triple negative breast cancer growth and metastasis by cross-talk with resistin
Mishra S, Ahiwar DK, Shukla RK, Chatterjee N, Ganju R. The Ohio State University, Columbus, OH.
P2-03-06 PTEN expression at the nexus of oncogenic signals in TNBC: Testing combination of p110beta-isoform-specific inhibitor with five PARP inhibitors
Dey N, Carlson JH, De P, Leyland-Jones B. Avera Cancer Institute, Sioux Falls, SD.
P2-03-07 Backwards translation: Exploring beta-adrenoreceptors (ßAR) in triple negative breast cancer (TNBC), a novel and druggable pathway
Spera G, Von Euw E, Fresco R, Slamon DJ. Medical Unit, Translational Research in Oncology (TRIO), Montevideo, Uruguay; Translational Oncology Research Laboratories (TORL), Los Angeles, CA.
P2-03-08 Preclinical evaluation of the PI3Kα/δ inhibitor, copanlisib in HER2+ breast cancer: A proof of concept study
De P, Carlson JH, Dey N, Leyland-Jones B. Avera Cancer Institute, Sioux Falls, SD.
P2-03-09 Autocrine motility factor signaling pathway promotes aggressive behavior and migration in breast cancer
Liu C, Price JD, Maroni D, Stevens JM, VanDyke AZ, Althof PA, Mondal P, Sanmann JN, Thayer SP. University of Nebraska Medical Center, Omaha, NE; Fred and Pamela Buffett Cancer Center, Omaha, NE; Human Genetics Laboratory, Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE.
P2-03-10 A cholesterol-derived oncometabolite and glucocorticoid receptor signaling in triple negative breast cancer cell proliferation
Mallinger A, Dalenc F, Poirot M, Silvente-Poirot S. Cholesterol Metabolism and Therapeutic Innovations, Cancer Research Center (CRCT), UMR 1037, Toulouse, France; Université Paul Sabatier, Toulouse, France; Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France.
P2-03-11 Genetic background determines the algorithm of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor
Carlson JH, De P, Dey N, Leyland-Jones B. Avera Cancer Institute, Sioux Falls, SD.
P2-03-12 Role of nucleus-specific intergenic long noncoding RNA-1476 in estrogen-dependent transcription in cancer
Choudhari R, Harrison AL, Carrillo CN, Gadad SS. Texas Tech University of Health Sciences Center, El Paso, TX.
   
  Tumor Cell and Molecular Biology: Virology
P2-04-01 Human papillomavirus (HPV) DNA detection in breast cancer by liquid biopsy: Something new on the horizon?
Bravaccini S, Ravaioli S, Rocca A, Maltoni R, Cristalli C, Marasco E, De Carolis S, Cricca M, Bonafè M. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy; Alma Mater Studiorum, University of Bologna, Bologna, Italy.
   
  Tumor Cell and Molecular Biology: Other
P2-05-01 Chemotherapy-induced metastasis: Mechanisms and translational opportunities
Rivera Sanchez LG, Karagiannis GS, Wang Y, Sharma VP, Burt J, Entenberg D, Oktay M, Condeelis JS. Albert Einstein College of Medicine, Bronx, NY.
P2-05-02 Age-related genetic and epigenetic changes in estrogen-receptor positive breast cancer
Schuster EF, Dowsett M. Breast Cancer Now Research Centre at The Institute of Cancer Research, London, United Kingdom; Ralph Lauren Centre for Breast Cancer Research at the Royal Marsden Hospital, London, United Kingdom.
P2-05-03 Clinical implication of APOBEC3A and 3B in Korean patients with breast cancer
Won HS, Sun DS, Ko YH, You SH, Kim YS, Kim JS. College of Medicine, The Catholic University of Korea, Seoul, Korea.
P2-05-04 The WNT pathway gene, LBH, is critically required for breast carcinogenesis by promoting tumor initiation and survival
Garikapati K, Chen P, Ashad-Bishop K, Briegel K. Braman Breast Cancer Institute at Sylvester Comprehensive Cancer Center; Miller School of Medicine, University of Miami, Miami, FL.
P2-05-05 Evaluation of pan-HER and c-MET inhibitors tested ex vivo in primary HER2- breast cancer cells with hyperactive c-MET and ErbB family signaling
Laing LG, Burns DJ, Khan S, MacNeil IA, Rich BE, Kharbush SM, Soltani SM, Sullivan BF. Celcuity Inc., Minneapolis, MN.
P2-05-06 Effects of a soy isoflavone in breast cancer treatment
Hatono M, Ikeda H, Taira N, Suzuki Y, Kajiwara Y, Kawata K, Takahashi Y, Tsukioki T, Kochi M, Iwamoto T, Shien T, Doihara H. Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama City, Japan.
P2-05-07 Differential expression and localization of beta-catenin and HSP27 after cisplatin/doxorubicin treatment in triple negative breast cancer cells
Pennacchio GE, Cordoba ME, Guerrero-Gimenez ME, Montt-Guevara MM, Cuello-Carrion D, Nadín SB, Vargas Roig ML, Fanelli MA. Institute of Medicine and Experimental Biology of Cuyo, (IMBECU) CONICET, Mendoza, Argentina; Faculty of Medical Sciences, National University of Cuyo, Mendoza, Argentina; Faculty of Medical, Mendoza University, Mendoza, Argentina; Molecular and Cellular Gynecological Endocrinology Laboratory (MCGEL), University of Pisa, Pisa, Italy.
P2-05-08 An assessment of the potential role of intracellular Ca2+ store regulators in breast cancer cells
Bong AH, Roberts-Thomson SJ, Milevskiy MJ, Monteith GR. School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia; The Walter and Eliza Hall of Medical Research, Parkville, Victoria, Australia; Mater Research Institute, Brisbane, Queensland, Australia.
P2-05-09 Withdrawn
   
  Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets
P2-06-01 The effect of a subcutaneous combination of testosterone (T) and anastrozole (Ai) (HAVAHT+Ai™) on volumetric mammographic breast density (MBD); an open labelled cohort study
Birrell SN, Dougherty D, Good SB, Birrell NJ, Rolan P. HAVAH Therapeutics Pty Ltd, Toorak Gardens, South, Australia; The University of Adelaide, Adelaide, South Australia, Australia; Wellend Clinic, Toorak Gardens, South Australia, Australia.
P2-06-02 Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Pratap UP, Altwegg KA, Li X, Srinivasan U, Ma S, Chang A, Riveros AC, Zhang KY, Dileep KV, Pan X, Murali R, Bajda M, Raj G, Brenner A, Manthati V, Rao M, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. UT Health and Mays Cancer Center, San Antonio; Evestra, Inc., San Antonio; Instituto de Química, Ciudad de, Mexico; RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan; Cedars-Sinai Medical Center, Los Angeles; Jagiellonian University, Cracow, Poland; UT Southwestern, Dallas.
P2-06-03 Insulin receptor isoform signaling in breast cancer
Zhang X, Chan JY, Pan Y, Dong C, Yee D. Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Peking University, Beijing, China.
P2-06-04 Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target
Grellety T, Callens C, Richard E, Pulido M, Goncalves A, Gestraud P, MacGrogan G, Bonnefoi H, Cardinaud B. INSERM UNIT U1218, Institut Bergonié, Bordeaux, France; Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France; Pharmacogenomic Unit, Genetics Laboratory, Institut Curie, Paris, France; Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux, France; Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Marseille, France; Institut Curie, PSL Research University, Mines Paris Tech, Bioinformatics and Computational Systems Biology of Cancer, INSERM U900, Paris, France; Bordeaux Institut National Polytechnique, Bordeaux, France.
P2-06-05 TP-0903, an AXL kinase inhibitor, reduces inflammatory breast cancer aggressiveness and macrophage polarization through additional mechanisms that may include JAK2 and Aurora B
Cheng Y, Funakoshi Y, Wang X, Warner SL, Bearss DJ, Ueno NT. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston; The University of Texas MD Anderson Cancer Center, Houston; Tolero Pharmaceuticals, Inc., Salt Lake City.
P2-06-06 Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer
Marczyk M, Gunasekharan V, Wali VB, Shi W, Patwardhan G, Qing T, Pusztai L, Hatzis C. Yale School of Medicine, New Haven; OrigiMed, Shanghai, China; Silesian University of Technology, Gliwice, Poland.
P2-06-07 Investigating the role of focal adhesion kinase in regulating CSC activity in invasive ductal carcinoma
Timbrell S, Aglan H, Cramer A, Foden P, Weaver D, Pachter J, Farnie G, Clarke R, Bundred N. Breast Biology Group, The University of Manchester, Manchester, United Kingdom; Academic Surgery, Manchester University Foundation Trust, Manchester, United Kingdom; The Christie, Manchester, United Kingdom; Verastem, Boston; Cellular Assays Group, The University of Oxford, Oxford, United Kingdom.
P2-06-08 Withdrawn
P2-06-09 Identification of oncogenic gene fusions in triple-negative breast cancer metastatic to the brain
Gonzalez-Ericsson P, Lehmann B, Mobley B, Chen Y-Y, Pietenpol J, Sanders ME. Vanderbilt University Medical Center/Vanderbilt Ingram Cancer Center, Nashville, TN; University of California at San Francisco, San Francisco, CA.
P2-06-10 Withdrawn
P2-06-11 Sortilin targeted therapy in breast cancer with elevated progranulin expression
Berger K, Rhost S, Hughes É, Harrison H, Rafnsdottir S, Jacobsson H, Gregersson P, Magnusson Y, Fitzpatrick P, Andersson D, Ståhlberg A, Landberg G. Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden; Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester, United Kingdom; Shore Lab, Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester, United Kingdom; Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academ, Göteborg, Sweden.
P2-06-12 Oncogenic potential of Trefoil factor 3 in initiation of mammary carcinoma through suppression of p53 pathway
Chen RM, Pandey V, Chong QY, Poh HM, Zhang MY, Kumar AP, Lobie PE. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Tsinghua Berkeley Shenzhen Institute, Tsinghua University Graduate School at Shenzhen, Shen Zhen, Guang Dong, China; National University Cancer Institute, Singapore, Singapore; Cancer Program, Medical Science Cluster, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
P2-06-13 A novel small molecule JMX0293 inhibits the growth of triple-negative breast cancer via suppressing STAT3 and inducing apoptosis
Dong J, Xu J, Kim H, Zhou J, Shen Q. The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas Medical Branch, Galveston, TX.
P2-06-14 The role of SLC7A5 (LAT1) in endocrine therapy-resistant breast cancer
Sevigny CM, Sengupta S, Luo Z, Jin L, Pearce D, Clarke R. Georgetown University, Washington, DC; The University of Edinburgh, Edinburgh, United Kingdom.
P2-06-15 Rational combination of Wee1 and BCL-2 inhibition in preclinical models of triple-negative breast cancer
Simmons DM, Tse TE, Dailey K, Hartman SJ, Bagsby S, Pitts TM, Tentler JJ, Diamond JR. University of Colorado Cancer Center, Aurora, CO.
P2-06-16 New targets in triple negative breast cancer: Role of Oncostatin M receptor pathway
Alvarez I, Araujo A, Abaurrea A, Rezola R, Urruticoechea A, Lawrie C, Caffarel MM. Biodonostia Health Research Institute, Donostia-San Sebastián, Gipuzkoa, Spain; Donostia University Hospital - Hospital Universitario Donostia, Donostia-San Sebastián, Gipuzkoa, Spain; Onkologikoa, Donostia-San Sebastián, Gipuzkoa, Spain.
P2-06-17 A novel interaction of AURKA with MAPK pathway in breast cancer cells as a potential therapeutic target
Gandhi S, Gil M, Khoury T, Takabe K, Puzanov I, Gelman I, D'Assoro A, Opyrchal M. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN.
P2-06-18 Withdrawn
P2-06-19 The effect of UBE2C expression on intrinsic chemosensitivity in breast cancer cell lines
Parris TZ, Larsson P, Biermann J, Engqvist H, Werner-Rönnerman E, Kovács A, Karlsson P, Helou K. University of Gothenburg, Sahlgrenska Cancer Center, Gothenburg, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden.
P2-06-20 CDC20 is a novel therapeutic target in triple negative breast cancer
Sharma J, Raicu I, Nguyen J, Udden N, Wang Q, Alluri P. University of Texas Southwestern Medical Center, Dallas, TX.
P2-06-21 Endogenous expression of ERβ variants contributes towards chemotherapy-resistance in the triple negative breast cancer cell line HCC-1806
Faria M, Gustafsson J-A, Strom A. University of Houston, Houston, TX.
P2-06-22 PEA15-AA, an unphosphorylatable mutant of PEA15, as a novel therapeutic gene for triple-negative breast cancer
Park J, Chauhan G, Cohen EN, Ueno NT, Battula VL, Tripathy D, Reuben JM, Bartholomeusz C. Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX.
P2-06-23 New biomarkers for adjuvant bisphosphonate use in triple-negative breast cancer
Sandholm JA, Petruk N, Selander KS, Tuomela JM. Cell Imaging Core, Turku Centre of Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland; University of Turku, Institute of Biomedicine, Turku, Finland; University of Oulu, Oulu, Finland.
P2-06-24 Cannabinoid receptors agonist induces lysosome-mediated cell death in TNBC
Chatterjee N, Das S, Ahiwar D, Mishra S, Kaul K, Ganju R. The Ohio State University, Wexner Medical Center, Columbus, OH.
P2-06-25 A phenotypic screening and machine learning platform efficiently identifies triple negative breast cancer-selective and readily druggable targets
Gautam P, Jaiswal A, Aittokallio T, Hassan A-A, Wennerberg K. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; University of Turku, Turku, Finland; University of Turku3The Miami Project to Cure Paralysis, Peggy and Harold Katz Family Drug Discovery Center, Sylvester Comprehensive Cancer Center, and University of Miami Miller School of Medicine, Miami, FL; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
   
  Prognostic and Predictive Factors: Prognostic Factor Index Scores
P2-07-01 Prediction model for lymphoedema, and effect of Lymphoedema diagnosis on quality of life (QoL) and distant recurrence from breast cancer
Bundred NJ, Foden P, Riches K, Morris J, Evans A, Todd C, Bramley M, Skene A, Purushotham A, Keeley V. Manchester University NHS Foundation Trust, Manchester, United Kingdom; Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom; Derby Hospitals NHS Foundation Trust, Derby, United Kingdom; Poole NHS Foundation Trust, Poole, United Kingdom; School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom; Pennine Acute Hospitals NHS Trust, Greater Manchester, United Kingdom; Royal Bournemouth NHS Foundation Trust, Bournemouth, United Kingdom; Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
P2-07-02 A newly derived combined clinical treatment score and immunohistochemical-4 prognostic tool
Dodson A, Sestak I, Bayani J, Dowsett M, Bartlett J, Cuzick J. Ralph Lauren Centre for Breast Cancer Research, The Royal Marsden Hospital, London, United Kingdom; Centre for Cancer Prevention, Queen Mary, University of London, London, United Kingdom; Ontario Institute of Cancer Research, Ontario, Canada.
P2-07-03 Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden
Hylton NM, Symmans WF, Yau C, Li W, Hatzis C, Isaacs C, Albain KS, Chen Y-Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien AJ, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey JC, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen PK, van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Sanil A, Berry SM, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, Rosen MA, Dogan B, Yang W, Joe B, I-SPY 2 TRIAL Consortium, Yee D, Pusztai L, DeMichele A, Asare SM, Berry DA, Esserman LJ. Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tucson, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philadelphia, PA; University of Southern California, Los Angeles, CA; University of Texas, M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Yale Cancer Center, New Haven, CT; Mayo Clinic, Scottsdale, AZ; University of Texas, Southwestern, Dallas, TX; Genentech, South San Francisco, CA; Gemini Group, Ann Arbor, MI.
P2-07-04 Prognostic value of residual cancer burden (RCB), neo-bioscore and neoadjuvant response index (NRI) to evaluate response to neoadjuvant trastuzumab-based therapy in HER2-positive breast cancer (BC)
Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Lips EH, Vrancken-Peeters M-JT, Horlings HM, Wesseling J, Sonke GS. The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.
P2-07-05 A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy
Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain.
P2-07-06 Cumulative copy number imbalances after neoadjuvant chemotherapy residual breast tumor is an independent predictor of relapse
Thompson PA, Brewster A, Tsavachidis S, Armstrong G, Do K-A, Ha M-J, Gutierrez C, Symmans F, Bondy M. Stony Brook School of Medicine, Stony Brook, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
P2-07-07 Development of a machine learning-based classifier for Oncotype DX® category prediction in a population of lymph node positive breast carcinoma patients
Beca F, Yang S-R, Gruber JG, Barry-Holson K, West R, Wen HY, Allison KH. Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY.
P2-07-08 Standardized prediction of Oncotype DX® risk classes by local RT-qPCR
Lehr H-A, Aulmann S, Etzrodt A, Laible M, Hartmann K, Gürtler C, Wirtz RM, Sahin U, Varga Z. Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany; OptiPath - MVZ für Pathologie, Frankfurt a.M., Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Stratifyer Molecular Pathology GmbH, Köln, Germany; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zürich, Switzerland.
P2-07-09 Immune recurrence score (IRS) using 7 immunoregulatory protein expression can predict recurrence in stage I-III breast cancer patients
Lee D-W, Ryu HS, Lee K-H, Jin M-S, Woo G-U, Suh KJ, Yang Y, Kim H-J, Lee H-B, Kim T-Y, Moon H-G, Han W, Park IA, Noh D-Y, Im S-A. Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Bucheon St. Mary's Hospital, Bucheon, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Chungbuk National University College of Medicine, Cheongju, Republic of Korea; Chung-Ang University College of Medicine, Seoul, Republic of Korea.
P2-07-10 Development of an NGS-based multigene assay to predict recurrence risk in hormone receptor-positive, HER2-negative, node-negative breast cancer
Lee H-B, Kim KE, Ju YW, Jung J-G, Ryu H-S, Lee SB, Lee JW, Lee HJ, Kim M-S, Kwon S, Kim J, Kim C, Moon H-G, Noh D-Y, Ahn S-H, Park I-A, Kim S, Yoon S, Kim A, Han W. Seoul National University Hospital, Seoul, Korea; Asan Medican Center, Seoul, Korea; Seoul National University College of Engineering, Seoul, Korea; Korea University Guro Hospital, Seoul, Korea.
P2-07-11 Prediction of the Oncotype Dx recurrence score (RS) from clinicopathologic factors
Voutsadakis IA, Thibodeau S, Reed M. Sault Area Hospital, Sault Ste Marie, ON, Canada; Northern Ontario School of Medicine, Sudbury, ON, Canada; Algoma University, Sault Ste Marie, ON, Canada.
P2-07-12 A prognostic prediction nomogram (PDIDC) for breast Paget's disease with infiltrating ductal carcinoma patients: A SEER cohort analysis
Tan L, Chen K, Jiang WG, You N, Wang Y, Sanders A, Liang G, Liu Z, Ling Y, Zhong W, Tian Z, Gong C. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China; School of Mathematics and Computational Science & Southern China Research Center of Statistical Science, Sun Yat-sen University, Guangzhou, Guangdong, China; Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom, Cardiff, Wales, United Kingdom.
P2-07-13 OncoproMex®: An intelligent decision support system for Mexican breast cancer patients
Armengol-Alonso A, Villalobos-Castaldi FM, Cabrera-Galeana P, Bargallo-Rocha E, Reynoso-Noverón N, Mohar A, Melo-Morin JP. Instituto Tecnológico Superior de Panúco, Veracruz, México; Instituto de Ciencias Aplicadas y Tecnología/ Universidad Nacional Autónoma de México, Mexico City, Mexico; Breast Medical Oncology Unit / Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Cancerología, Mexico City, Mexico; Epidemiology Breast Cancer Unit / Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Ciencias Médicas y Nutrición Dr Salvador Zubirán, Mexico City, Mexico.
   
  Prognostic and Predictive Factors: Other
P2-08-01 Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database
Huober J, Schneeweiss A, Blohmer J-U, Denkert C, Tesch H, Hanusch CA, Salat C, Rhiem K, Rezai M, Solbach C, Fasching PA, Jackisch C, Mehta K, Nekljudova V, Seither F, von Minckwitz G, Loibl S, Untch M. Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany.
P2-08-02 Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer
Schmid P, Pinder S, Wheatley D, Zummit C, Macaskill EJ, Hu J, Price R, Bundred N, Hadad S, Shia A, Sarker S-J, Lim L, Mousa K, O'Brien C, Wilson TR, Lackner MR, Gendreau S, Gazinska P, Korbie D, Trau M, Mainwaring P, Thompson A, Purushotham A. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston.
P2-08-03 Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence and an increased risk of breast cancer mortality in women with ductal carcinoma in situ treated with breast-conserving therapy
Rakovitch E, Sutradhar R, Lalani N, Gu S, Nofech-Mozes S, Hanna W, Fong C, Paszat L. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
P2-08-04 Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET)
Sestak I, Martin M, Dubsky P, Rojo F, Cuzick J, Filipits M, Ruiz A, Buus R, Hlauschek D, Rodriguez-Lescure A, Dowsett M, Gnant M. Centre for Cancer Prevention, Queen Mary University London, London, United Kingdom; Hospital General Universitario Gregorio Marañón, GEICAM, Madrid, Spain; Klinik St. Anna, Lucerne, Switzerland; CIBERONC-ISCIII Fundación Jiménez Díaz, GEICAM, Madrid, Spain; Medical University of Vienna, Vienna, Austria; The Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom; Austrian Breast and Colorectal Study Group, ABCSG, Vienna, Austria; Instituto Valenciano de Oncología, GEICAM, Valencia, Spain; Hospital Universitario de Elche, GEICAM, Valencia, Spain.
P2-08-05 Withdrawn
P2-08-06 Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer
Pascual T, Tsai YS, Martín M, Lluch A, Cortes J, Llombart A, Conte P, Guarneri V, Rimawi MF, Alba E, Ruiz-Borrego M, Rojo F, de la Haba J, Schiff R, Adamo B, Vidal M, Paré L, Chic N, Muñoz M, Galvan P, Gonzalez-Farre B, Brauer HA, Sullivan A, Nuciforo P, Parker JS, Prat A. Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; IDIBAPs, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Hospital Clinico Universitario, Valencia, Spain; Biomedical Research Institute INCLIVA, Valencia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; 1Hospital Arnau de Vilanova, Valencia, Spain; University of Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, Padova, Italy; Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and Baylor St. Luke's Medical Center, Houston; Hospital Universitario Virgen de la Victoria, IBIMA, Malaga, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Fundación Jiménez Díaz, Madrid, Spain; Reina Sofía University Hospital, Cordoba, Spain; NanoString Technologies, Inc, Seattle; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
P2-08-07 Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2- breast cancer
Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Brigham and Women's Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Stanford University, Palo Alto, CA; University of Colorado Cancer Center, Aurora, CO; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Genomic Health Inc., Redwood City, CA.
P2-08-08 Isolated ipsilateral local recurrence of breast cancer: Predictive factors and prognostic impact
Houvenaeghel G, de Nonneville A, Cohen M, Classe J-M, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo P-E, Gimbergues P, Chauvet M-P, Azuar A-S, Rouzier R, Tunon de Lara C, Murraciole X, Agostini A, Gonçalves A, Lambaudie E. Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France; Institut René Gauducheau, Site Hospitalier Nord, St Herblain, France; Institut Curie, Paris, France; Institut Gustave Roussy, Paris, France; Centre Léon Bérard, Lyon, France; Centre Claudius Regaud, Toulouse, France; Hôpital Tenon, Paris, France; Centre Georges François Leclerc, Dijon, France; Centre Val d'Aurelles, Montpellier, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Oscar Lambret, Lille, France; Hôpital de Grasse, Grasse, France; Hôpital René Huguenin, Saint Cloud, France; Institut Bergonié, Bordeaux, France; Hôpital de la Timone, Marseille, France; Hôpital de la Conception, Service de Gynécologie Obstétrique, Marseille, France.
P2-08-09 Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
Orucevic A, McNeil ML, Bell JL, McNabb AP, Heidel RE. University of Tennessee Medical Center, Graduate School of Medicine, Knoxville, TN; University of Tennessee Health Science Center, College of Medicine, Memphis, TN.
P2-08-10 Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials
Villegas SL, Lederer B, Untch M, Holms F, Ulmer H-U, Diebold K, Fasching PA, Weber K, Schmitt WD, Tesch H, Rezai M, Marmé F, Sinn B, Hackmann J, Schneeweiss A, Tannapfel A, Nekljudova V, Denkert C, Loibl S. Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany.
P2-08-11 Tumor infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer
Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Esposito A, Viale G, Curigliano G. European Istitute of Oncology, Milano, Italy.
P2-08-12 Development and validation of prognostic gene signatures for basal-like breast cancer and high grade serous ovarian cancer
Hu H, Zhang Y, Liu J, Raj-Kumar P-K, Yang H, Lee M, Kovatich AJ, Shriver CD. Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Center for Cancer Research, National Cancer Institute, Rockville, MD; Clinical Breast Care Project, Murtha Cancer Center Research Program, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD; Murtha Cancer Center Research Program, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD.
P2-08-13 Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status
Kornaga EN, Matutino AR, Pereira AA, Verma S, Lupichuk S. Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil; University of Calgary, Calgary, Canada.
P2-08-14 Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial
Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Tonghua L, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno Aspitia A, Piccart M, Loi S, de Azambuja E. Institut Jules Bordet and Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Frontier Science, Kingussie, United Kingdom; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; European Institute of Oncology (IEO) and University of Milan, Milan, Italy; Mayo Clinic, Phoenix, AZ; Peking Union Medical College Hospital, Beijing, China; Breast International Group (BIG), Brussels, Belgium; National Cancer Institute, Bethesda, MD; Novartis Pharma AG, Basel, Switzerland; Mayo Clinic, Jacksonville, FL; Sana Klinikum Offenbach, Offenbach, Germany; Johns Hopkins School of Medicine, Baltimore, MD; Institut Gustave Roussy, Villejuif, France; Hospital de Santa Maria and Instituto de Medicina Molecular, Lisbon, Portugal; Hospital Clínic of Barcelona, Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia.
P2-08-15 Metabolic syndrome and early-stage breast cancer outcome: Results from a prospective observational study
Buono G, Crispo A, Giuliano M, Rea CG, Forestieri V, Lauria R, De Placido P, De Laurentiis M, Pacilio C, Grimaldi M, Nocerino F, Montella M, De Placido S, Arpino G. University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy.
P2-08-16 Impact of germline BRCA mutation status on survival in women with metastatic triple negative breast cancer
Larson K, Wang YY, Finke K, O'Dea AP, Khan Q, Nye L, Heldstab J, Godwin AK, Kimler BF, Sharma P. University of Kansas Medical Center, Kansas City, KS; University of Kansas Medical Center, Westwood, KS.
P2-08-17 Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study
Pascual T, Pernaut C, Tolosa P, Galvan P, Bárcena C, Vidal M, Manso L, Adamo B, Dueñas M, Muñoz M, Chic N, Gonzalez-Farre B, Villagrasa P, Ciruelos E, Prat A. Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; IDIBAPs, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital 12 de Octubre, Madrid, Spain.
P2-08-18 Tumor microenvironment of metastasis (TMEM) score in residual breast carcinoma post-neoadjuvant chemotherapy as an independent prognosticator of distant recurrence
Oktay MJ, D'Alfonso T, Ginter P, Lanjewar S, Entenberg D, Pastoriza JM, Wang Y, Lin Y, Karagiannnis GS, Lin J, Ye X, Anampa J, Xue X, Rohan TE, Sparano JA, Condeelis JS. Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY.
P2-08-19 Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)
Wongchenko MJ, Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, Singel SM, Maslyar DJ, Xu N, de la Peña L, Baselga J, Gendreau S, Isakoff SJ. Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA.
P2-08-20 Prognostic impact of SRC, CDKN1B and JAK2 expression in metastatic breast cancer patients treated with trastuzumab
Economopoulou P, Kotoula V, Koliou G-A, Papadopoulou K, Christodoulou C, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Pectasides D, Kotsakis A, Razis E, Samantas E, Kalogeras KT, Economopoulos T, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
P2-08-21 Mismatch repair protein loss is a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability
Fusco N, Lopez G, Corti C, Pesenti C, Colapietro P, Ercoli G, Gaudioso G, Faversani A, Gambini D, Despini L, Blundo C, Vaira V, Miozzo M, Ferrero S, Bosari S. University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy; Breast Surgery Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
P2-08-22 Clinical implication of HER2/neu status in hormone receptor positive pure mucinous breast cancer
Gwark S-C, Lee JW, Lee SB, Sohn G, Kim J, Chung IY, Ko BS, Kim HJ, Son BH, Ahn SH. Asan Medical Center, Seoul, Republic of Korea.
P2-08-23 A combined score of tumour budding and tumour necrosis has prognostic value for cancer specific survival in both ER positive and ER negative primary operable breast cancer
Morrow ES, Gujam F, Mohammed Z, McMillan DC, Horgan PG, Roseweir AK, Edwards J. Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Academic Unit of Surgery, University of Glasgow, Glasgow, United Kingdom; Omar El-Mukhtar University, Albeida, Libyan Arab Jamahiriya.
P2-08-24 The average modified Magee score can be helpful in predicting an Oncotype DX recurrence score ≤ 25
Turner BM, Sanders MA, Breaux A, Soukiazian A, Soukiazian N, Hicks DG. University of Rochester Medical Center, Rochester, NY; University of Louisville, Louisville, KY; University of Rochester, Rochester, NY; Drexel University College of Medicine Graduate School of Biomedical and Professional Studies, Philadelphia, PA.
P2-08-25 PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer
Zerdes I, Sifakis E, Matikas A, Tobin NP, Charlotte R, Rassidakis GZ, Bergh J, Foukakis T. Cancer Centrum Karolinska, Karolinska Institute, Stockholm, Sweden; Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden.
P2-08-26 High expression of CYP27A1 in breast cancer is associated with poor tumor pathological features and may differentially predict prognosis depending on menopausal status
Kimbung S, Stålhammar T, Inasu M, Nodin B, Elebro K, Tryggvadottir H, Jirström K, Rose C, Ingvar C, Jernström H, Borgquist S. Lund University, Lund, Sweden; CREATE Health and Department of Immunotechnology, Lund University, Lund, Sweden; Aarhus University Hospital, Aarhus, Denmark.
P2-08-27 Does a large breast protect against axillary nodal spread in breast carcinoma?
Rayen JM, Poole GH, Rhodes C. Middlemore Hospital, Auckland, New Zealand; Auckland University, Auckland, New Zealand.
P2-08-28 Relationship between FDG uptake and neutrophil/lymphocyte ratio in patients with breast invasive ductal cancer
Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T. Gunma University, Maebashi, Japan.
P2-08-29 The impact of time interval between diagnosis and surgery in each type and stage of breast cancer
Kim J-M, Choi HJ, Kim I, Ryu JM, Yu J, Lee JE, Kim SW, Nam SJ, Lee SK. Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
P2-08-30 Vitamin D as a prognostic factor in triple negative early breast cancer
Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, Santacana M, Canosa Morales C, Mele Olivé J. Hospital Universitari Arnau de Vilanova, Lleida, Spain.
P2-08-31 Predictive and prognostic value of stromal tumor-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer
Ochi T, Giampaolo B, Murai M, Nozaki F, Kobayashi D, Iwamoto T, Niikura N, Suzuki K, Yamauchi H, Hayashi N. St. Luke's International Hospital, Tokyo, Japan; San Raffaele Scientific Institute, Milan, Italy; Okayama University Hospital, Okayama, Japan; Tokai University School of Medicine, Isehara, Japan.
P2-08-32 Withdrawn
P2-08-33 A novel seven-gene signature predicts prognosis in early-stage triple-negative breast cancer
Ren Y, Jiang Y, Zuo W, Xu X, Jin X, Ma D, Shao Z. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-08-34 The network metanalysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials: Progression free survival (PFS) benefit from first-line endocrine-based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups
Rossi V, Giannarelli D, Berchialla P, Montemurro F, Ferretti G, Nistico' C, Vigna L, Cognetti F, Fabi A. Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy.
P2-08-35 A significance of SUVmax levels on FDG-PET as a prognostic factor may be mediated by local immune environment of breast cancer
Fujimoto Y, Higuchi T, Watanabe T, Hida AI, Imamura M, Kitajima K, Miyoshi Y. Hyogo College of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
P2-08-36 Comparing prognostic performance of different lymph node staging systems among patients with breast cancer
Gong Y, Ji P, Jiang Y-Z, Hu X, Shao Z-M. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-08-37 The prognostic impact of synaptojanin 2 expression in estrogen receptor α-positive breast cancer patients
Nishikawa S, Kondo N, Wanifuchi-Endo Y, Hisada T, Uemoto Y, Katagiri Y, Dong Y, Kato H, Takahashi S, Toyama T. Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
P2-08-38 Influence of prognostic factors on outcomes among metastatic breast cancer patients treated with CDK4&6 inhibitors in routine clinical practice
Saverno KR, Carter GC, Li L, Battiato LA, Huang Y-J, Smyth EN, Price GL, Sheffield KM, Baxi SS, Kuk D, Seidman AD. Eli Lilly and Company, Indianapolis, IN; Flatiron Health, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY.
P2-08-39 Predictors of distant metastasis in patients with triple negative breast cancer who failed to achieve a pathological complete response after neoadjuvant chemotherapy
Tricarico CJ, Gabani P, Weiner AA, Ochoa LL, Thomas MA, Zoberi I. Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC.
P2-08-40 Reconsidering “at risk” criteria for breast cancer recurrence in hormone positive patients: Risk stratification is still important in patients with an Oncotype Dx recurrence score ≤ 25!
Turner BM, Sanders MAG, Soukiazian A, Soukiazian N, Hicks DG. University of Rochester Medical Center, Rochester, NY; University of Louisville, Louisville, KY; University of Rochester, Rochester, NY; Drexel University College of Medicine Graduate School of Biomedical and Professional Studies, Philadelphia, PA.
P2-08-41 Biology, metastases pattern and survival of triple negative breast cancer (TNBC) – A comparison between younger (<40 years) and elderly (>74 years) patients
Tzikas A-K, Nemes S, Linderholm BK. Institution of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden; Institution of Clinical Sciences, Gothenburg University, Gothenburg, Sweden.
P2-08-42 Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients
Yan F, Master AK, Israel MA, Liu J, Zhang Y, Schnabel CA, Gadi VK. University of Washington/Fred Hutchinson Cancer Research Center, Seattle; University of California Los Angeles, Los Angeles; Biotheranostics, Inc., San Diego.
P2-08-43 Can optoacoustic imaging combined with ultrasound non-invasively offer prognosis for breast cancer molecular subtypes?
Menezes GL, Mann RM, Meeuwis C, Bisschops B, Veltman J, Lavin PT, van de Vijver MJ, Pijnappel RM. UTHSCSA, San Antonio; Radboud University Medical Center, Nijmegen, Netherlands; Rijnstate Hospital, Arnhem, Netherlands; Albert Schweitzer Hospital, Dordrecht, Netherlands; ZGT, Almelo, Netherlands; Boston Biostatistics Research Foundation, Framingham; Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands.
P2-08-44 Tumor infiltrating lymphocytes in triple negative breast cancer: Our experience at an Argentine breast unit
Allemand C, Calvo MF, Valerio AC, Riggi MC, Corrao F, Orti R, Wernicke A, Zamora L, Paez MC, Lorusso C. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
P2-08-45 Malic enzyme 1 is a potential metastasis-related biomarker of breast cancer
Liu C, Tao Z, Hu X. Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.
P2-08-46 Prognostic value of tumor-infiltrating lymphocytes (TILs) and clinical values for prediction of breast cancer recurrence in HER2 positive early breast cancer after surgery in King Chulalongkorn Memorial Hospital
Prapatsornvichit S, Atikankul T, Sriuranpong V, Poovorawan N, Parinyanitikul N. King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
P2-08-47 Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)
Fontaine C, Van den Eynden G, de Wind R, Boisson A, Renard V, Van den Bulck H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, De Grève J, Awada A, Wildiers H, Willard-Gallo K. UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium.
P2-08-48 Features associated with long-term survival in metastatic breast cancer
Klar NJ, Rosenzweig M, Diergaarde B, Brufsky A. University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh School of Nursing, Pittsburgh, PA; Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA.
P2-08-49 The role of neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR) andmonocyte – lymphocyte ratio (MLR) in prognosis of breast cancer patients
Huszno J, Kołosza Z, Mrochem Kwarciak J, Rutkowski T, Składowski K. MSC Memorial Cancer Centere and Institute of Oncology, Gliwice, Silesia, Poland; MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Silesia, Poland.
P2-08-50 Elevated levels of serum tumor marker p53 is a prognostic parameter and a monitoring biomarker for patients who had undergone surgical resection in breast cancer
Arai M, Nagata T, Sekine S, Baba H, Moriyama M, Hashimoto I, Fujii T. University of Toyama, Toyama, Japan.
P2-08-51 Residual Ki67 index and PRPTD mutational status after neoadjuvant chemotherapy containing platinum salts predicts the survival in triple negative breast cancer
Huang L. DFudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China.
P2-08-52 A predictive model for distant metastasis in breast cancer patients using machine learning
Kim I, Choi HJ, Ryu JM, Lee SK, Yu JH, Kim SW, Nam SJ, Seo SW, Lee JE. Samsung Medical Center, Seoul, Gangnam-Gu, Korea.
P2-08-53 Tumor elasticity and clinicopathologic factors affecting neoadjuvant chemotherapy response in breast cancer patients
Park JY, Choi JE, Bae YK, Lee SJ. Yeungnam University College of Medicine, Daegu, Republic of Korea.
P2-08-54 Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal patients
Villarreal-Garza C, Deneken-Hernandez Z, Maffuz-Aziz A, Lopez-Martinez EA, Muñoz-Lozano JF, Barragan-Carrillo R, Peña-Curiel O, Moreno B, Ramos-Elias P, Diaz H, Bautista-Piña V. Tecnologico de Monterrey, Breast Cancer Center, Monterrey, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; Fundacion de Cancer de Mama (FUCAM), Mexico City, Mexico.
P2-08-55 Expression of MTH1 correlates with prognostic factor in breast cancer
Zhang H, Liu T-H, Zhang L-Q, Li J, Cui J, Tian X-Y, Li D-N, Cai J-P. Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, China.
P2-08-56 Effects of young age on prognosis in patients with node-negative tumors 2 cm or smaller breast cancer
Zhong W, Tan L, You N, Wang Y, Liang G, Liu Z, Ling Y, Tian Z, Gong C. Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, Guangzhou, China; Sun Yat-Sen University, Guangdong, Guangzhou, China.
P2-08-57 A biologic signature to predict ipsilateral breast event risk at 10 years for early breast cancer
Bremer T, Savala J, Leesman G, Wärnberg F, Sund M, Wadsten C, Whitworth PW. PreludeDx, Laguna Hills, CA; Uppsala University, Uppsala, Sweden; Umeå University, Umeå, Sweden; Nashville Breast Center, Nashville, TN.
P2-08-58 Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage?
Fernandez S, Garcia A, Vethencourt A, Vazquez S, Petit A, Pla MJ, Ortega R, Pérez J, Gil M, Ponce J, Pernas S, Lopez A, Falo C. Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain.
P2-08-59 Different predictive and prognostic impact of intra-tumor heterogeneity, tumor biology, and microenvironment in triple negative breast cancer
Hayashi N, Nakamura M, Kobayashi D, Suzuki K, Yamauchi H. St. Luke's International Hospital, Tokyo, Japan.
P2-08-60 Withdrawn
P2-08-61 FOXA1, Nestin, GATA3 and mammaglobin expression in 164 breast cancer metastases – A retrospective immuno-histochemical study of a 10-year period (2004-2014)
Nyqvist J, de Lara S, Parris TZ, Helou K, Kenne Sarenmalm E, Einbeigi Z, Karlsson P, Kovács A. Department of Surgery, Lidköping, Sweden; Department of Pathology, Gothenburg, Sweden; Department of Oncology, Gothenburg, Sweden; Sahlgrenska Center of Cancer Research, Gothenburg, Sweden; Center of Research and Education, Skaraborgs Hospital, Skövde, Sweden.
P2-08-62 Predicting survival of triple negative breast cancer using artificial neural networks
Osman MH. Faculty of Medicine, Zagazig University, Zagazig, Egypt.
P2-08-63 The relationship between serum level of copper and ceruloplasmin and pathologic and clinical characteristics in early breast cancer patients
Fan J, Wan Y, Zhao G, Wang T. Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China; Fourth Military Medical University, Xi'an, Shaanxi, China.
P2-08-64 Patterns and predictors of early failure in women with triple negative breast cancer
Nichols EM, Cherng H-R, Rice SR, Hamza M, Murali S, Tkaczuk K, Bellavance E, Cheston SB, Amin N, Rosenblatt P. University of Maryland School of Medicine, Baltimore, MD.
P2-08-65 A single-center real-world observational study to explore clinical treatments and prognoses of the Chinese patients with breast cancer complicated with brain metastases
Ouyang Q, Tang Y, Hu Z, Tian C, Xie N, Liu L, Xiao H, Li J, Wu H, Yang X, Yang C. Hunan Cancer Hospital, Changsha, China; Hunan Cancer Hospital, Chasha, China; Linkdoc (Beijing) Technology Co. Ltd, Beijing, China.
P2-08-66 Outcomes among metastatic breast cancer patients with characteristics that confer a less favorable prognosis
Saverno K, Cuyun Carter G, Dufour R, Price G, Li L, DeLuca A, Nash Smyth E, Battiato L, Gable J, Walker MS, Huang Y-J, Hannas S, Schwartzberg LS. Eli Lilly and Company, Indianapolis, IN; Vector Oncology, Memphis, TN; West Cancer Center, Germantown, TN.
   
  Treatment: Immunotherapy (Clinical)
P2-09-01 Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients
Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD.
P2-09-02 Modulation of the immune microenvironment in high risk DCIS by intralesional injection of anti-PD-1 (pembrolizumab)
Campbell MJ, McCune E, Rothschild H, Bolen J, VandenBerg S, Chien J, Wong J, Esserman L. University of California, San Francisco, CA.
P2-09-03 Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count
Page DB, Pucilowska J, Bennetts L, Kim I, Sanchez K, Martel M, Conlin A, Moxon N, Mellinger S, Acheson A, Kemmer K, Mitri Z, Vuky J, Ahn J, Abaya C, Manigault T, Basho R, Urba WJ, McArthur HL. Earle A. Chiles Research Institute, Portland, OR; OHSU Knight Cancer Institute, Portland, OR; Cedars-Sinai Medical Center, Los Angeles, CA.
P2-09-04 Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+ breast cancer
Reimann H, Nguyen A, Hübner H, Erber R, Bausenwein J, Van der Meijden ED, Lux MP, Jud S, Griffioen M, Rauh C, Sanborn JZ, Benz SC, Rabizadeh S, Beckmann MW, Mackensen A, Rübner M, Fasching PA, Kremer AN. University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany; NantOmics, LLC, Santa Cruz, CA; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany; NantOmics, LLC, Culver City, CA; Leiden University Medical Center, Leiden, The Netherlands.
P2-09-05 LCCC 1525: A phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (mTNBC)
Anders CK, Moore D, Sambade M, Cuaboy L, Garrett A, Woodcock M, McKinnon K, Cowens K, Bortone D, Calhoun B, Carey L, Dees C, Jolly T, Muss H, Reeder-Hayes K, Kaltman R, Jankowitz R, Gudena V, Olajide O, Perou C, Vincent B, Serody J. The University of North Carolina at Chapel Hill, Chapel Hill, NC; George Washington University Cancer Center, Washington, DC; University of Pittsburgh Cancer Center, Pittsburgh, PA; Cone Health Cancer Center, Greensboro, NC; Rex Hematology/Oncology Associates (Rex Hospitals), Raleigh, NC.
P2-09-06 Safety and efficacy of stereotactic body radiotherapy and Pembrolizumab in advanced breast cancer patients with 1 to 5 metastases
David SP, Savas P, Neeson PJ, Luen SJ, Foroudi F, Siva S, Loi S. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Olivia Newton John Cancer Centre, Melbourne, Victoria, Australia.
P2-09-07 Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC)
McArthur HL, Basho R, Shiao SL, Park D, Mita M, Chung A, Arnold B, Martin C, Dang C, Karlan S, Knott S, Giuliano A, Ho A. Cedars-Sinai Medical Center, Los Angeles, CA; Massachusetts General Hospital, Boston, MA.
P2-09-08 Imprime PGG, a novel innate immune modulator, combined with pembrolizumab in a phase 2 multicenter, open label study in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
O'Day S, Borges V, Chmielowski B, Ruta R, Abu-Khalaf M, Stopeck A, Lowe J, Mattson P, Breuer K, Gargano M, Bose N, Uhlik M, Graff J, Chisamore M, Cox J, Osterwalder B. John Wayne Cancer Institute, Santa Monica, CA; UCHealth University of Colorado, Aurora, CO; Ronald Reagan UCLA Medical Center, Los Angeles, CA; Rush University Medical Center, Chicago, IL; Sidney Kimmel Cancer Center, Philadelphia, PA; SUNY Stony Brook Cancer Center, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ; B.O. Consulting GmbH, Riehen, Switzerland.
P2-09-09 Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
Bhattacharya S, Holmes JP, Calfa C, Lukas J, Tan-Chiu E, Clifton GT, Peoples GE, Lacher M, Wiseman CL, Williams WV. Thomas Jefferson University, Philadelphia, PA; Redwood Reg Medcl Grp, Santa Rosa, CA; University of Miami, Miami, FL; The Everett Clinic, Everett, WA; Florida Cancer Specialists and Research Institute, Parkland, FL; Cancer Insight, San Antonio, TX; BriaCell Therapeutics Corporation, Berkeley, CA.
P2-09-10 Epigenetic modulation—unlocking the potential of checkpoint inhibition in breast cancer
Roussos Torres ET, Rafie C, Armstrong T, Jaffee EM. Johns Hopkins University, Baltimore, MD.
P2-09-11 Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer
Telli ML, Zablotsky K, Le MH, Canton D, Browning E, Bannavong D, Gargosky S, Wapnir I. Stanford University School of Medicine, Stanford, CA; OncoSec Medical, San Diego, CA.
P2-09-12 Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC)
Pucilowska J, Egan JE, Berinstein NL, Moxon N, Aliabadi-Wahle S, Imatani JH, Conlin A, Acheson A, Massimino K, Martel M, Campbell M, Wu Y, Sun Z, Redmond W, Shah M, Urba WJ, Page DB. Earle A. Chiles Research Institute, Portland, OR; IRX Therapeutics, New York, NY; University of Toronto, Toronto, ON, Canada; The Oregon Clinic, Portland, OR.
P2-09-13 A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)
Specht JM, Lee SM, Turtle C, Berger C, Balakrishnan A, Srivastava S, Viollet V, Veatch J, Gooley T, Mullane E, Chaney CN, Rader C, Pierce RH, Gottardo R, Maloney DG, Riddell SR. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; Scripps Florida, Jupiter, FL.
P2-09-14 Immunogenomic pathway and survival analysis in breast cancers based on tumor location and molecular subtypes
Shen Y, Shyu C-R, Mitchem JB, Ding F, Shajahan-Haq AN. Informatics Institute, University of Missouri, Columbia, MO; Hamden Hall Country Day School, Hamden, CT; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
P2-09-15 A phase I study of interferon-gamma (γ)plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
Han HS, Khong H, Costa R, Loftus L, Goodridge D, Henry T, Soliman H, Ismail-Khan R, Fridley B, Czerniecki B. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
P2-09-16 CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients
Crosby EJ, Gwin WR, Chang S, Maecker HT, Lubkov V, Snyder JC, Broadwater G, Hyslop T, Osada T, Hobeika AC, Hartman ZC, Morse MA, Lyerly HK. Duke University, Durham, NC; University of Washington, Seattle, WA; Stanford University, Stanford, CA.
   
  Treatment: Antiangiogenic Therapy (Adjuvant and Metastatic)
P2-10-01 Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer
Zhu A, Yuan P, Wang J, Fan Y, Luo Y, Cai R, Zhang P, Li Q, Ma F, Xu B. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
P2-10-02 AVASTEM – Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for locally advanced breast cancers: A prospective proof of concept randomized phase II trial
Sabatier R, Charafe-Jauffret E, Pierga J-Y, Curé H, Lambaudie E, Houvenaeghel G, Ginestier C, Sfumato P, Extra J-M, Gonçalves A. Institut Paoli-Calmettes, Marseille, France; Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille, France; Institut Curie, Paris, France; Institut Jean Godinot, Reims, France; Department of Clinical Research and Innovation, Biostatistics Unit, Marseille, France.
   
  Treatment: Antibody-Based Regimens
P2-11-01 Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
Kalinsky K, Isakoff SJ, Tolaney SM, Juric D, Mayer IA, Vahdat LT, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Shah NC, Abramson V, Goldenberg DM, Sharkey RM, Washkowitz SA, Wegener WA, Iannone R, Bardia A. Columbia University-Herbert Irving Comprehensive Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; The Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Weill Cornell Medicine, New York, NY; University of Colorado Cancer Center, Aurora, CO; Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, TX; UF Health Cancer Center, Orlando, FL; Yale University School of Medicine, New Haven, CT; Immunomedics, Inc., Morris Plains, NJ.
   
  Treatment: Signal Transduction Inhibitors
P2-12-01 Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study
Gee J, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Finlay P, Cheung A, Cullberg M, de Bruin E, Foxley A, Koulai L, Pass M, Schiavon G, Rugman P, Deb R, Robertson JFR. Cardiff University, Cardiff, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Poole Hospital NHS Foundation Trust, Poole, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Leicester Royal Infirmary, Leicester, Leicestershire, United Kingdom; Kings Mill Hospital, Mansfield, Nottinghamshire, United Kingdom; Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire, United Kingdom; University of Dundee, Dundee, United Kingdom; AstraZeneca, Pepparedsleden 1, Sweden; AstraZeneca, Melbourn, Hertfordshire, United Kingdom; Royal Derby Hospital, Derby, Derbyshire, United Kingdom; University of Nottingham, Nottingham, Nottinghamshire, United Kingdom.
P2-12-02 Discovery of the β-catenin/Tcf inhibitors for treatment of triple negative breast cancer
Ji H, Wang Z, Mo C, Zhang M. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
   
  Treatment: Adjuvant Therapy
P2-13-01 Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial
Gnant M, Martin M, Holmes F-A, Jackisch C, Chia SK, Iwata H, Moy B, Martinez N, Mansi J, Morales S, Ruiz-Borrego M, von Minckwitz G, Buyse M, Delaloge S, Bhandari M, Murias Rosales A, Galeano T, Fujita T, Luczak A, Barrios CH, Saura C, Rugo HS, Chien J, Johnston SR, Spencer M, Xu F, Barnett B, Chan A, Ejlertsen B. Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain; Texas Oncology, Houston, TX; Sana Klinikum Offenbach, Offenbach, Germany; British Columbia Cancer Agency, Vancouver, Canada; Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan; Massachusetts General Hospital Cancer Center, Boston, MA; Hospital Universitario Ram[oacute]n y Cajal, Madrid, Spain; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, United Kingdom; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; German Breast Group, Neu-Isenburg, Germany; International Drug Development Institute, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Christ Hospital of Cincinnati, Cincinnati, OH; Compejo Hospitalario Materno Insular de Las Palmas, Las Palmas, Spain; Magna Graecia University, Catanzaro, Italy; Jichi Medical University Hospital, Tochigi, Japan; Aalborg Sygehus, Aalborg, Denmark; Centro de Pesquisa em Oncologia HSL, PUCRS, Porto Alegre, Brazil; Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology, VHIO, Barcelona, Spain; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Royal Marsden NHS Foundation Trust, London, United Kingdom; Puma Biotechnology Inc., Los Angeles, CA; Breast Cancer Research Centre-Western Australia and Curtin University, Nedlands, Australia; Rigshospitalet, Copenhagen, Denmark.
P2-13-02 Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
P2-13-03 The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials
Delaloge S, Hurvitz S, Chan N, Bose R, Jankowitz RC, Thirlwell M, Láng I, ten Tije A, Trudeau M, Osborne CR, Shen Z-Z, Lalla D, Xu F, Hunt D, Olek E, Tripathy D, Rugo HS, Chien J, Chan A, Barcenas CH. Institut Gustave Roussy, Villejuif, France; UCLA Hematology / Oncology Clinical Research Unit, Los Angeles, CA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Washington University School of Medicine, St. Louis, MO; UPMC Magee-Womens Hospital, Breast Center, Pittsburgh, PA; McGill University Health Centre Cedars Cancer Centre, Montreál, Canada; Orszagos Onkologiai Intezet "B" Belgyogyaszati Osztaly, Budapest, Hungary; Amphia Ziekenhuis, Breda, Netherlands; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada; Texas Oncology, PA and US Oncology, Dallas, TX; Shanghai Cancer Center, Fudan University, Shanghai, China; Puma Biotechnology Inc., Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Breast Cancer Research Centre-Western Australia and Curtin University, Nedlands, Australia.
P2-13-04 Impact of the adjuvant treatment with trastuzumab in HER2 positive breast cancer in the real-world setting. Analysis of two cohorts (1997-2005/2006-2015) in 1970 patients
Rodriguez CA, Garcia-Gomez J, Ribelles N, Gavila J, Pernas S, Rodriguez-Lescure A, Urrutikoetxea A, Pernaut C, Lopez A, Garcia-Mata J. Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain; Complejo Hospitalario de Orense, Orense, Spain; Hospital Universitario Virgen de la Victoria, Malaga, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Instituto Catalan de Oncologia, L'Hospitalet, Barcelona, Spain; Hospital General Universitario de Elche, Elche, Alicante, Spain; Onkologikoa, San Sebastian, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Complejo Asistencial Universitario de Leon, Leon, Spain.
P2-13-05 Prevalence of trastuzumab-induced cardiotoxicity in a real-world setting
Calvillo-Argüelles O, Flores-Diaz D, Gonzalez-Serrano J-P, López-Rojas A, Mendoza-Galindo L, Matus-Santos J-A, Reynoso-Noverón N, Cabrera-Galeana P, Bargalló-Rocha E, Arce-Salinas C. Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico.
P2-13-06 Long term clinical follow up of real world HER2-positive patients since the introduction of trastuzumab
Ellegard S, Asowed M, Engvall K, Hallbeck A-L, Elander N, Stål O. Department of Clinical and Experimental Medicine and Department of Oncology, Linköping, Sweden; Ryhov County Hospital, Jönköping, Sweden.
P2-13-07 Efficacy of short-course adjuvant trastuzumab in early stage breast cancer
Saifo M, Nikoula M. Al Bairouny University Hospital, Damascus, Syrian Arab Republic.
   
  Treatment: Surgery
P2-14-01 The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL
Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, I-SPY 2 TRIAL Consortium, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision Oncology, Sioux Falls, SD; University of Texas, M.D. Anderson Cancer Center, Houston, TX; Quantum Leap Healthcare Collaborative, San Francisco, CA; Berry Consultants, LLC, Houston, TX.
P2-14-02 Get skin sparing mastectomy right: Reduce local recurrence rate by meticulous removal all breast tissue
Drabble EH. Derriford Hospital, Plymouth, United Kingdom.
P2-14-03 Longitudinal changes in psychosocial health in young women following breast cancer surgery: Results from a multi-center cohort study
Rosenberg SM, Hu J, Dominici LS, Poorvu PD, Ruddy KJ, Tamimi RM, Schapira L, Come S, Peppercorn JM, Borges VF, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA; Beth Israel Deaconess Medical Center, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Colorado Cancer Center, Aurora, CO.
P2-14-04 Genetic testing and bilateral mastectomy for women with breast cancer: Does testing matter more than the test result?
Verdial FC, Bartek MA, Anderson BO, Javid SH. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.
P2-14-05 Can an internal surgical adhesive facilitate drain-free mastectomy and reduce overall invasiveness?-A prospective, randomized, controlled, multicenter non-inferiority trial
Eichler C, Paepke S, Ohlinger R, Mathias W, Scheffen I, Lux M, Hadad S, Kiernan T, Whisker L, Kaushik M, King P. Kliniken der Stadt Köln, Brustzentrum, Köln, Germany; St. Elisabeth Krankenhaus, Brustzentrum, Köln, Köln, Germany; Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Erlangen, Germany; Universitätsklinik Greifswald, Interdisziplinäres Brustzentrum, Greifswald, Greifswald, Germany; University Hospitals of Leicester, Leicester, Leicester, United Kingdom; Royal Cornwall Hospital, Cornwall, Cornwall, United Kingdom; Klinik und Poliklinik für Frauenheilkunde Technische Universität München, Brustzentrum, München, Germany; Royal Hallamshire Hospital, Sheffield, Sheffield, United Kingdom; St. Helens and Knowsley Teaching Hospitals, St. Helens, St. Helens, United Kingdom; Nottingham University Hospitals, Nottingham, Nottingham, United Kingdom.
P2-14-06 Withdrawn
P2-14-07 Use of an activatable cell penetrating peptide-fluorescent imaging agent (AVB-620) to identify positive and close margins intraoperatively
Chen SL, Baron PL, Lee MC, Feldman SM, McLaughlin SA, Terando AM, Harootunian A, Poonka P, Gonzalez JE. Avelas Biosciences, Inc, La Jolla, CA; Roper St. Francis, Charleston, SC; Moffitt Cancer Center, Tampa, FL; Montefiore Hospital and Medical Center, Bronx, NY; Mayo Clinic, Jacksonville, FL; Ohio State University, Columbus, OH.
P2-14-08 Clinicopathological features and prognosis of nipple–areola and skin flap recurrence after nipple-sparing mastectomy for breast cancer over 20 years
Sakurai T, Suzuma T, Yoshimura G, Sasaki E, Umemura T, Sakurai T. Wakayama Medical University, Kihoku Hospital, Ito Gun Katsuragi Cho, Wakayama, Japan; Kushimoto Arida Hospital, Kushimoto, Wakayama, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan; Kiwa Hospital, Hashimoto, Wakayama, Japan; Sakurai Breast Clinic, Wakayama, Wakayama, Japan.
P2-14-09 A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer patients
Seki H, Sakurai T, Shimizu K, Mizuno S, Tokuda T, Kaburagi T, Seki M, Karahashi T, Nakajima K. Saitama Medical Center, 4-9-3 Kitaurawa, Urawa City, Saitama, Japan; Division of Pathology, 4-9-3 Kitaurawa, Urawa City, Saitama, Japan.
P2-14-10 Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer patients: A longitudinal cohort study
Wang K, Shi Y, Zhang X, Ren G-S, Li H-Y. The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; West China School of Public Health, Sichuan University, Chengdu, Sichuan, China.
P2-14-11 Mechanisms involved in hypnosis analgesia explaining potential benefits observed among breast cancer patients undergoing breast surgery
Berliere M, Piette N, Gerday A, Roelants F, Docquier M-A, Piette P, Duhoux F, Watremez C. Cliniques Universitaires Saint-Luc, Brussels, Belgium; Grand Hpital de Charleroi, Charleroi, Belgium.
P2-14-12 Impact of the time interval between neoadjuvant chemotherapy and surgery in Latin-Americans breast cancer patients
Rebaza LP, Galarreta JA, Castañeda C, Cotrina JM, Vilchez S, de la Cruz M, Ponce J, Aguilar A, Flores C, Castillo M, Galvez M, Vigil C. ONCOSALUD - AUNA, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
P2-14-13 Single institute data to assess timing of surgery post neoadjuvant in breast cancer patients
Suleman K, Haque E, Mushtaq AH, Badran A, Alsayed A, Ajarim D, Twegieri T, Almalik O, Jastaniyah NT, Elhassan T, Alkhayal W. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Alfaisal University, Riyadh, Saudi Arabia.
P2-14-14 Voice of cancer patients (VoCP): Analysis of experiences of cancer patients undergoing breast cancer surgery
Aggarwal S, Sharma R, Bhoemick J, Singh M, Aggarwal A. Santa Clara Valley Medical Center, San Jose, CA; Scry Analytics India PVT, Gurgaon, Harayana, India; Scry Analytics. INC, San Jose, CA.
P2-14-15 Breast cancer-related lymphedema: Morbidity of sentinel node biopsy
Ju YW, Jung JG, Kim KE, Kim Y, Lee E, Lee H-B, Moon H-G, Han W, Noh D-Y. Seoul National University College of Medicine, Seoul, Republic of Korea.
P2-14-16 Comparison of robotic nipple sparing mastectomy (R-NSM) to endoscopic assisted nipple sparing mastectomy (E-NSM) in the management of breast cancer
Lai H-W, Chen S-T, Chen D-R, Kuo S-J. Changhua Christian Hospital, Changhua, Taiwan.
P2-14-17 Long-term oncologic safety of nipple-sparing mastectomy with immediate reconstruction
Yamashita Y, Hayashi N, Nagura N, Kajiura Y, Yoshida A, Takei J, Suzuki K, Tsunoda H, Yamauchi H. St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan.
P2-14-18 Achieving rapid intrao-operative diagnosis during breast cancer surgery using high-resolution full-field optical coherence imaging and dynamic cell imaging
Yang H, Zhang S, Guo J, Xie F, Tong F, Cao Y, Liu P, Zhou B, Cheng L, Liu M, Wang S, Peng Y, Wang C, Yang Y, Ma Y, Chen D, Shen D, Wang S. Peking University Peoples' Hospital, Beijing, China.
P2-14-19 Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer
Haddad SA, Spring LM, Jimenez RB, Vidula N, Comander A, Shin JA, Coopey SB, Gadd MA, Hughes KS, Taghian A, Smith BL, Isakoff SJ, Moy B, Bardia A, Specht MC. Massachusetts General Hospital, Boston, MA.
P2-14-20 Early locoregional breast surgery improves overall and progression-free survival in oligometastatic breast cancer
Hotton J, Lusque A, Rauch P, Leufflen L, Buhler J, Pierret M, Salleron J, Marchal F. Lorraine Cancer Institute, Vandoeuvre-les-Nancy, France; Faculté of Medicine, Lorraine University, Vandoeuvre-les-Nancy, France; Biostatistic Unit, Toulouse Universitary Cancer Institute, Toulouse, France; Biostatistic Unit, Lorraine Cancer Institute, Vandoeuvre-les-Nancy, France; CNRS, CRAN, UMR 7039, Vandoeuvre-les-Nancy, France.
P2-14-21 The effects of poloxamer and sodium alginate mixture (Guardix-SG®) on range of motion after axillary lymph node dissection: A single-center, prospective, randomized, double-blind pilot study
Lee S, Ahn SH, Lee JW, Chung IY, Ko BS, Kim HJ, Kim J, Shon G, Son BH. Asan Medical Center, Seoul, Republic of Korea.
P2-14-22 Is sentinel lymph node biopsy necessary in breast cancer patients who were diagnosed as initially clinically node-negative before neoadjuvant chemotherapy?
Fujita T, Sakuragi M, Miyazaki C, Shiba S, Tanaka Y, Nishida S. Jichi Medical University, Tochigi, Japan.
P2-14-23 Successful intraoperative margin assessment in DCIS and invasive breast cancer with diffuison-weighted MRI using the Clearsight™ system
Thill M, Kelling K, van Haasteren V, Traub L, Nölke J, Szwarcfiter I, Shapiro M, Schon A, Aulmann S. Agaplesion Markus Hospital, Frankfurt am Main, Hessen, Germany; Clearcut, Rehovot, Israel; OptiPath, Frankfurt am Main, Germany.
P2-14-24 Argon scalpel in the surgical treatment of breast cancer
Giordano R, Bromberg S, Elias S, Nazário A, Waitzberg A, Sá R, Facina G. Federal University of Sao Paulo - UNIFESP, Sao Paulo, Brazil.
P2-14-25 Application of robotic surgery (da Vinci) in the management of breast cancer- Preliminary results and experience sharing
Lai H-W, Chen S-T, Chen D-R, Kuo S-J, Lin S-L. Changhua Christian Hospital, Changhua, Taiwan.
P2-14-26 Withdrawn
P2-14-27 Impact of surgery on survival in patients with stage IV breast cancer: A population-based study from the SEER database
Song C-G, Lin Y-X, Zhang J, Zeng Q, Chen M-Y, Chen L-L, Wang X-X, Chen Q-X. Affiliated Union Hospital of Fujian Medical University, Fuzhou, China; First Affiliated Hospital of Fujian Medical University, Fuzhou, China; Fujian Provincial Maternity and Children Health Hospital, Fuzhou, China.
P2-14-28 Local surgery improves survival in patients with primary metastatic breast cancer: A population-based study
Zhao Y, Sun H, Yang X, Zhao Y, Chen M, Jin W. Fudan University Shanghai Cancer Center, Shanghai, China; Fudan University, Shanghai, China.
P2-14-29 Image guided surgery for tumor detection in breast cancer using the PH activated micellar tracer ONM-100: The SHINE study
Steinkamp PJ, Voskuil FJ, Koller M, van der Vegt B, Doff JJ, Zhao T, Hartung J, Jayalakshmi Y, Sumer BD, Gao J, Witjes MJ, van Dam GM. University Medical Center Groningen, University of Groningen, Groningen, Netherlands; Onconano Medicine, Dallas, TX; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; JPH Clinical Development Inc, San Diego, CA.
P2-14-30 Survival outcomes of breast conserving surgery versus mastectomy for ultrasound detected non-palpable breast cancer in hospital-based screening among Chinese women
Yao R, Pan B, Xu Y, Zhou Y, Zhu Q, Zhang J, Wu H, Mao F, Lin Y, Shen S, Sun Q. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.